SynthesisUrologic oncology2020
Urologic oncology practice during COVID-19 pandemic: A systematic review on what can be deferrable vs. nondeferrable.
Synthesis in Urologic oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Research advances in extracellular vesicles for diagnosis and treatment of genitourinary cancers.Frontiers in cell and developmental biology · 2026Review
- The COVID-19 pandemic and Urology - reflecting on successful initiatives and lessons in Australia.BJU international · 2025Review
- Changes in Urologic Cancer Surgical Volume and Length of Stay During the COVID-19 Pandemic in Pennsylvania.JAMA network open · 2023Article
- A Retrospective Analysis of the Challenges of Urothelial Cancer Management during the COVID-19 Pandemic at a Single Academic Center in Romania.Healthcare (Basel, Switzerland) · 2023Article
- The Impact of Covid-19 Pandemic on Genitourinary Cancers Stage and Grade.Clinical genitourinary cancer · 2023Article
- Association between COVID-19 Burden, Population Vaccination Status, and Urologic Oncology Surgery Volume: A National Multicenter Cross-Sectional Study.Journal of clinical medicine · 2022Article
- Impact of the First Wave of COVID-19 Pandemic on Radiotherapy Practice at Tata Memorial Centre, Mumbai: A Longitudinal Cohort Study.JCO global oncology · 2022Article
- Impact of the COVID-19 Pandemic on Urologic Oncology Surgery: Implications for Moving Forward.Journal of clinical medicine · 2021Article
- Urothelial carcinoma in COVID-19: lessons from a pandemic and their impact on clinical practice.Future oncology (London, England) · 2021Article
- Cancer management during the COVID-19 pandemic: Choosing between the devil and the deep blue sea.Critical reviews in oncology/hematology · 2021Review
- Racial and Ethnic Disparities in Preoperative Surgical Wait Time and Renal Cell Carcinoma Tumor Characteristics.Healthcare (Basel, Switzerland) · 2021Article
- Impact of CoVID-19 on resident and fellow education: Current guidance and future opportunities for urologic oncology training programs.Urologic oncology · 2021Article
- Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond.Urologic oncology · 2021Article
- Assessing patient risk from cancer and COVID-19: Managing patient distress.Urologic oncology · 2021Review
- Risk of Covid-19 infection after resection of high grade transitional cell carcinoma with renal impairment.International journal of surgery case reports · 2021Article
- Management of urologic cancers during the pandemic and potential impact of treatment deferrals on outcomes.Urologic oncology · 2021Article
- The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic.Frontiers in oncology · 2021Review
- Living in a rural area as a risk factor for worst outcomes in penile cancer.International braz j urol : official journal of the Brazilian Society of UrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo provide a review of high-risk urologic cancers and the feasibility of delaying surgery without impacting oncologic or mortality outcomes. MATERIALS AND
methodsA thorough literature review was performed using PubMed and Google Scholar to identify articles pertaining to surgical delay and genitourinary oncology. We reviewed all relevant articles pertaining to kidney, upper tract urothelial cell, bladder, prostate, penile, and testicular cancer in regard to diagnostic, surgical, or treatment delay.
resultsThe majority of urologic cancers rely on surgery as primary treatment. Treatment of unfavorable intermediate or high-risk prostate cancer, can likely be delayed for 3 to 6 months without affecting oncologic outcomes. Muscle-invasive bladder cancer and testicular cancer can be treated initially with chemotherapy. Surgical management of T3 renal masses, high-grade upper tract urothelial carcinoma, and penile cancer should not be delayed.
conclusionThe majority of urologic oncologic surgeries can be safely deferred without impacting long-term cancer specific or overall survival. Notable exceptions are muscle-invasive bladder cancer, high-grade upper tract urothelial cell, large renal masses, testicular and penile cancer. Joint decision making among providers and patients should be encouraged. Clinicians must manage emotional anxiety and stress when decisions around treatment delays are necessary as a result of a pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.